The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer

European Journal of Surgical Oncology

Volumn 25, Issue 4, 1999, Pages 356-363

  Clahsen, P C ^a,b,c   Van De Velde, C J H ^b   Duval, C ^d   Pallud, C ^e   Mandard, A M ^f   Delobelle Deroide, A ^g   Van Den Broek, L ^c   Van De Vijver, M J ^c,h  

^a EORTC DATA CENTER   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d CENTRE HENRI BECQUEREL   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Ki 67; Oestrogen receptor; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS INDEX; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TUMOR BIOPSY;

EID: 0033180397     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0657     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 399: 1-15, 71-85.
2. Anonymous. Clinical alert from the National Cancer Institute, May 18, 1988. Breast Cancer Res Treat 1988; 12: 3-5.
3. Anonymous. NIH consensus conference 1990. Treatment of early-stage breast cancer. JAMA 1991; 265: 391-5.
4. Fisher B, Redmond C, Fisher ER, Caplan R, and other contributing National Surgical Adjuvant Breast and Bowel Project Investigators. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognostic in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 1076-87.
5. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. New Engl J Med 1989; 320: 627-33.
6. Baak JPA, van Dop H, Kurver PHJ, Herman J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374-82.
7. Clahsen PC, van de Velde CJH, Julien J-P, Floiras J-L, Mignolet FY, and cooperating investigators. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European organization for research and treatment of cancer breast cancer cooperative group study. J Clin Oncol 1994; 12: 1266-71.
8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
9. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
10. European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group. Manual for Clinical Research in Breast Cancer. EORTC Monograph. Leuven, Belgium, 1991.
11. Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C, Key G, d'Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993; 171: 83-98.
12. Wintzer H-O, Zipfel I, Schulte-Mönting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991; 67: 421-8.
13. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71: 3926-31.
14. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey RW, Nicholson RI. Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 1989; 59: 943-7.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
17. Cox DR. Regression models and life-tables. J R Stat Assoc 1972; B34: 187-220.
18. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982; 45: 361-6.
19. Clahsen PC, Van de Velde CJH, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van den Brock L, Sahmoud TM, van de Vijver MJ. Prognostic factors in premenopausal node-negative women with early breast cancer. Eur J Cancer 1994; 30A (Suppl. 2): S18 (abstract).
20. King WJ, DeSombre ER, Jensen EV, Greene GL. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 1985; 45: 293-304.
21. Pertschuk LP, Eisenberg KB, Carter AC, Feldman JG. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer 1985; 55: 1513-8.
22. Jonat W, Maass H, Stegner HE. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 1986; 46 (Suppl.): 4296s-8s.
23. McClelland RA, Berger U, Miller LS, Powles TJ, Jensen EV, Coombes RC. Immunocytochemical assay for estrogen receptor: Relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 1986; 46 (Suppl.): 4241s-3s.
24. Esteban JM, Ahn C, Battifora H, Felder B. Predictive value of estrogen receptors evaluated by quantitative immunohistochemistry analysis in breast cancer. Am J Clin Pathol 1994; 102: S9-12.
25. Isola JJ, Helin HJ, Helle MJ, Kallioniemi O-P. Evaluation of cell proliferation in breast carcinoma. Comparison of ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer 1990; 65: 1180-4.
26. Sahin AA, Ro J, Ro JY, Blick MB, El-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer 1991; 68: 549-57.
27. De la Rochefordière A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand J-C, Poullart P, Magdelenat H, Forquet A. Age as a prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-43.
28. Albain KS, Allred DC, Clark GM, Breast cancer outcome and predictors of outcome: Are there age differentials? Monogr Natl Cancer Inst 1994; 16: 35-42.
29. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Canolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris J. Relationship of patients' age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12: 818-94.
30. Remvikos Y, Magdelenat H, Dutrillaux B. Genetic evolution of breast cancers. III: Age-dependent variations in the correlation between biological indicators of prognosis. Breast Cancer Res Treat 1995; 34: 25-33.
31. Clark GM, Hilsenbeck S. Integration of prognostic factors: Can we predict breast cancer recurrence? In Schmitt M, et al. (eds) Prospects in Diagnosis and Treatment of Breast Cancer 1994: 177-86.